n.n.store(600712)2024-10-28 10:07Financial Performance - The company's operating revenue for the third quarter was ¥137,515,224.65, a decrease of 18.07% compared to the same period last year[2]. - The net profit attributable to shareholders for the third quarter was ¥3,213,317.59, while the net profit for the year-to-date was ¥5,632,092.69, reflecting a decrease of 16.66%[2]. - Total operating revenue for the first three quarters of 2024 was CNY 424,682,699.03, a decrease of 16.7% compared to CNY 509,600,680.04 in the same period of 2023[14]. - Net profit for the first three quarters of 2024 was CNY 5,632,092.69, compared to a net loss of CNY 18,338,423.99 in the same period of 2023[16]. - Operating profit for the first three quarters of 2024 was CNY 6,119,584.01, a significant improvement from a loss of CNY 18,452,928.71 in 2023[15]. - Basic and diluted earnings per share for the first three quarters of 2024 were CNY 0.0103, compared to a loss of CNY 0.0337 in the same period of 2023[18]. - The company reported a basic earnings per share of CNY 0.0244 for the first three quarters of 2024, compared to a loss per share of CNY -0.0042 in the same period of 2023[25]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date was -¥29,694,312.25, a significant decrease of 144.56%[2]. - In the first three quarters of 2024, the net cash flow from operating activities was -29,694,312.25 RMB, compared to 66,642,843.11 RMB in the same period of 2023, indicating a significant decline[19]. - Total cash inflow from operating activities was 701,454,731.11 RMB, down from 1,002,942,150.55 RMB year-over-year, reflecting a decrease of approximately 30%[19]. - The cash outflow from operating activities totaled 731,149,043.36 RMB, compared to 936,299,307.44 RMB in the previous year, showing a reduction of about 22%[19]. - The company’s cash and cash equivalents at the end of the period were 64,206,866.79 RMB, down from 153,399,286.15 RMB at the end of 2023, reflecting a decrease of approximately 58%[20]. - The company's cash flow from operating activities showed a net outflow of CNY 29,534,199.35, compared to a net inflow of CNY 170,816,306.94 in the same period of 2023[26]. - The cash and cash equivalents at the end of the period were CNY 51,035,808.82, down from CNY 131,538,035.88 at the end of the previous year[26]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,404,661,456.01, a decrease of 6.91% from the previous year[4]. - Total liabilities were RMB 552,356,743.83, slightly down from RMB 564,343,411.92, reflecting a decrease of about 2.0%[12]. - Total liabilities as of the end of the reporting period were CNY 570,687,765.00, down from CNY 680,598,548.90 in the previous year[13]. - The total assets as of September 30, 2024, were 1,886,065,795.12 RMB, a decrease from 1,931,116,600.00 RMB at the end of 2023[22]. - Current liabilities totaled 781,603,198.17 RMB, an increase from 755,243,712.38 RMB at the end of 2023, indicating a rise of about 3%[22]. - The total liabilities decreased to 787,456,856.84 RMB from 845,823,992.87 RMB at the end of 2023, indicating a decline of approximately 7%[22]. Shareholder Information - The top shareholder, Nanning Weining Investment Group Co., Ltd., holds 20.11% of the shares[8]. - Total equity attributable to shareholders was CNY 833,973,691.01, an increase from CNY 828,341,598.32 in the previous year[13]. - There are no significant changes in the top 10 shareholders or their participation in margin financing activities[10]. Operating Costs and Expenses - Total operating costs for the first three quarters of 2024 were CNY 437,760,146.01, down from CNY 529,692,452.44 in 2023, reflecting a reduction of 17.4%[15]. - The company reported a decrease in sales expenses to CNY 44,436,725.51 from CNY 57,135,721.10 in the previous year, a reduction of 22.2%[15]. - The company reported a decrease in sales expenses to CNY 27,600,096.02 from CNY 36,905,443.63 in the same period of 2023, indicating cost control measures[24]. - The company reported a decrease in employee compensation payments to 64,335,760.75 RMB from 71,504,984.87 RMB year-over-year, a reduction of about 10%[19]. - The company's financial expenses included interest expenses of CNY 6,762,964.84, slightly up from CNY 6,598,945.06 in the previous year[24]. Investments and Income - The company reported non-operating income of ¥833,246.40 for the year-to-date, primarily from the disposal of non-current assets and government subsidies[5]. - The company has seen an increase in investment income from its associate company, Nanning Pharmaceutical Co., Ltd.[7]. - The company reported a significant increase in long-term equity investments, rising to RMB 40,995,337.59 from RMB 30,784,921.06, which is an increase of about 33.8%[12]. Research and Development - Research and development expenses were not specified but are included in the total operating costs, which decreased overall[15]. - The company incurred research and development expenses, although specific figures were not disclosed in the provided documents[24]. - The company has not indicated any new product launches or technological developments during this reporting period[10]. - The company has not provided specific guidance for future performance or new product developments in the current report[16].